319 related articles for article (PubMed ID: 20023894)
1. The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes.
Ronconi L; Fregona D
Dalton Trans; 2009 Dec; (48):10670-80. PubMed ID: 20023894
[TBL] [Abstract][Full Text] [Related]
2. Noble metal-dithiocarbamates precious allies in the fight against cancer.
Nagy EM; Ronconi L; Nardon C; Fregona D
Mini Rev Med Chem; 2012 Oct; 12(12):1216-29. PubMed ID: 22931593
[TBL] [Abstract][Full Text] [Related]
3. Promising anticancer mono- and dinuclear ruthenium(III) dithiocarbamato complexes: systematic solution studies.
Nagy EM; Nardon C; Giovagnini L; Marchiò L; Trevisan A; Fregona D
Dalton Trans; 2011 Nov; 40(44):11885-95. PubMed ID: 21971872
[TBL] [Abstract][Full Text] [Related]
4. Zinc(II) complexes with dithiocarbamato derivatives: structural characterisation and biological assays on cancerous cell lines.
Nagy EM; Sitran S; Montopoli M; Favaro M; Marchiò L; Caparrotta L; Fregona D
J Inorg Biochem; 2012 Dec; 117():131-9. PubMed ID: 23085593
[TBL] [Abstract][Full Text] [Related]
5. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.
Ronconi L; Giovagnini L; Marzano C; Bettìo F; Graziani R; Pilloni G; Fregona D
Inorg Chem; 2005 Mar; 44(6):1867-81. PubMed ID: 15762713
[TBL] [Abstract][Full Text] [Related]
6. Rational design of gold(III)-dithiocarbamato peptidomimetics for the targeted anticancer chemotherapy.
Kouodom MN; Boscutti G; Celegato M; Crisma M; Sitran S; Aldinucci D; Formaggio F; Ronconi L; Fregona D
J Inorg Biochem; 2012 Dec; 117():248-60. PubMed ID: 22877925
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours.
Margiotta N; Ostuni R; Gandin V; Marzano C; Piccinonna S; Natile G
Dalton Trans; 2009 Dec; (48):10904-13. PubMed ID: 20023921
[TBL] [Abstract][Full Text] [Related]
8. DNA cleavage and antitumour activity of platinum(II) and copper(II) compounds derived from 4-methyl-2-N-(2-pyridylmethyl)aminophenol: spectroscopic, electrochemical and biological investigation.
Roy S; Maheswari PU; Lutz M; Spek AL; den Dulk H; Barends S; van Wezel GP; Hartl F; Reedijk J
Dalton Trans; 2009 Dec; (48):10846-60. PubMed ID: 20023915
[TBL] [Abstract][Full Text] [Related]
9. Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents.
Wang X; Guo Z
Dalton Trans; 2008 Mar; (12):1521-32. PubMed ID: 18335133
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, molecular structure and evaluation of new organometallic ruthenium anticancer agents.
Camm KD; El-Sokkary A; Gott AL; Stockley PG; Belyaeva T; McGowan PC
Dalton Trans; 2009 Dec; (48):10914-25. PubMed ID: 20023922
[TBL] [Abstract][Full Text] [Related]
11. Beyond platinums: gold complexes as anticancer agents.
Nardon C; Boscutti G; Fregona D
Anticancer Res; 2014 Jan; 34(1):487-92. PubMed ID: 24403506
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes.
Giovagnini L; Ronconi L; Aldinucci D; Lorenzon D; Sitran S; Fregona D
J Med Chem; 2005 Mar; 48(5):1588-95. PubMed ID: 15743200
[TBL] [Abstract][Full Text] [Related]
13. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
14. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Lazarević T; Rilak A; Bugarčić ŽD
Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative activity of dmoPTA-Ru(II) complexes against human solid tumor cells.
Ríos-Luci C; León LG; Mena-Cruz A; Pérez-Roth E; Lorenzo-Luis P; Romerosa A; Padrón JM
Bioorg Med Chem Lett; 2011 Aug; 21(15):4568-71. PubMed ID: 21719285
[TBL] [Abstract][Full Text] [Related]
16. The status of platinum anticancer drugs in the clinic and in clinical trials.
Wheate NJ; Walker S; Craig GE; Oun R
Dalton Trans; 2010 Sep; 39(35):8113-27. PubMed ID: 20593091
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological studies of some gold(I) complexes containing functionalised alkynes.
Schuh E; Valiahdi SM; Jakupec MA; Keppler BK; Chiba P; Mohr F
Dalton Trans; 2009 Dec; (48):10841-5. PubMed ID: 20023914
[TBL] [Abstract][Full Text] [Related]
18. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
Nardon C; Brustolin L; Fregona D
Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
[TBL] [Abstract][Full Text] [Related]
19. Copper, gold and silver compounds as potential new anti-tumor metallodrugs.
Tan SJ; Yan YK; Lee PP; Lim KH
Future Med Chem; 2010 Oct; 2(10):1591-608. PubMed ID: 21426151
[TBL] [Abstract][Full Text] [Related]
20. Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties.
Ronconi L; Marzano C; Zanello P; Corsini M; Miolo G; Maccà C; Trevisan A; Fregona D
J Med Chem; 2006 Mar; 49(5):1648-57. PubMed ID: 16509581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
